• Publications
  • Influence
Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses
Urinary excretion data and plasma metabolite/parent compound concentration ratio data suggested that capacity-limited formation of the active metabolite may account, at least in part, for the nonlinear pharmacokinetics of clarithromycin.
Absolute bioavailability of clarithromycin after oral administration in humans
Pharmacokinetic analysis of the parent drug and the active 14-hydroxy metabolite data suggests complete (or nearly complete) absorption of the drug after oral administration, suggesting that marked first-pass metabolism of clarithromycin occurs after oraladministration.
Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey.
Drug‐Food Interaction Potential of Clarithromycin, A New Macrolide Antimicrobial
Results suggest that clarithromycin can be taken without regard to timing in relation to meals and that metabolite area under the plasma concentration‐time curve was increased.
Clarithromycin Pharmacokinetics in Healthy Young and Elderly Volunteers
Differences in parent and metabolite pharmacokinetic parameters were small and the increase in circulating drug concentrations was well tolerated (no increase in incidence or severity of adverse events), adjustments in clarithromycin dosing regimens may not be necessary solely on the basis of age.
Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration.
A group of six normal adult male volunteers was divided into two groups who received bolus intravenous and subcutaneous 1-mg doses of leuprolide and the differences between the mean values of k21, k12, kel, apparent volume of distribution of the central compartment, mean residence time, and area under the moment curve for the routes of administration were significant.
Single‐ and Multiple‐dose Pharmacokinetics of Clarithromycin, a New Macrolide Antimicrobial
Plasma accumulation of metabolite occurred to a much lesser degree than that of the parent compound despite a substantially longer t1/2 for the metabolite, which would suggest that formation of this metabolite is capacity‐limited and that this may in part account for the nonlinearity observed in clarithromycin pharmacokinetics.